UY33144A - Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana - Google Patents

Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana

Info

Publication number
UY33144A
UY33144A UY0001033144A UY33144A UY33144A UY 33144 A UY33144 A UY 33144A UY 0001033144 A UY0001033144 A UY 0001033144A UY 33144 A UY33144 A UY 33144A UY 33144 A UY33144 A UY 33144A
Authority
UY
Uruguay
Prior art keywords
human
protein
hangptl4
angiopoyetin
diseases
Prior art date
Application number
UY0001033144A
Other languages
English (en)
Spanish (es)
Inventor
Chen Gang
Sleeman Mark
Gusarova Viktoria
Jee H Kim
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY33144A publication Critical patent/UY33144A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
UY0001033144A 2009-12-24 2010-12-22 Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana UY33144A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US30635910P 2010-02-19 2010-02-19
US32831610P 2010-04-27 2010-04-27
US34927310P 2010-05-28 2010-05-28
US35612610P 2010-06-18 2010-06-18

Publications (1)

Publication Number Publication Date
UY33144A true UY33144A (es) 2011-06-30

Family

ID=43629324

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033144A UY33144A (es) 2009-12-24 2010-12-22 Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana

Country Status (30)

Country Link
US (2) US8354103B2 (cg-RX-API-DMAC7.html)
EP (1) EP2516466B1 (cg-RX-API-DMAC7.html)
JP (2) JP6000855B2 (cg-RX-API-DMAC7.html)
KR (1) KR101842570B1 (cg-RX-API-DMAC7.html)
CN (1) CN102741284A (cg-RX-API-DMAC7.html)
AR (1) AR079708A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010336369C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012017765A2 (cg-RX-API-DMAC7.html)
CA (1) CA2785158C (cg-RX-API-DMAC7.html)
CY (1) CY1118898T1 (cg-RX-API-DMAC7.html)
DK (1) DK2516466T3 (cg-RX-API-DMAC7.html)
ES (1) ES2628135T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170524T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034722T2 (cg-RX-API-DMAC7.html)
IL (1) IL220402A (cg-RX-API-DMAC7.html)
JO (1) JO3274B1 (cg-RX-API-DMAC7.html)
LT (1) LT2516466T (cg-RX-API-DMAC7.html)
MX (1) MX337082B (cg-RX-API-DMAC7.html)
NZ (1) NZ600768A (cg-RX-API-DMAC7.html)
PL (1) PL2516466T3 (cg-RX-API-DMAC7.html)
PT (1) PT2516466T (cg-RX-API-DMAC7.html)
RS (1) RS56009B1 (cg-RX-API-DMAC7.html)
RU (1) RU2580045C2 (cg-RX-API-DMAC7.html)
SG (1) SG181784A1 (cg-RX-API-DMAC7.html)
SI (1) SI2516466T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700280T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488643B (cg-RX-API-DMAC7.html)
UY (1) UY33144A (cg-RX-API-DMAC7.html)
WO (1) WO2011079257A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204507B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2758535B1 (en) * 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
AU2013245630A1 (en) * 2012-04-13 2014-10-30 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
KR20150041662A (ko) 2012-08-13 2015-04-16 리제너론 파아마슈티컬스, 인크. Ｐｈ-의존적 결합 특성을 갖는 항-ｐｃｓｋ9 항체
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
MX2015016978A (es) * 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
DK3092491T3 (en) * 2014-01-07 2019-02-11 Bioatla Llc Proteins that are targeted orthologs
AP2017009721A0 (en) * 2014-08-07 2017-01-31 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3541839A1 (en) 2016-11-17 2019-09-25 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
US11046764B2 (en) 2017-01-03 2021-06-29 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND COMPOSITIONS AND METHODS COMPRISING THEM
WO2021037007A1 (zh) 2019-08-29 2021-03-04 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
WO2021119019A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
TW202218682A (zh) * 2020-07-02 2022-05-16 美商瑪柏里提克斯公司 細胞結合蛋白及使用方法
WO2023239307A1 (en) * 2022-06-10 2023-12-14 Nanyang Technological University Methods of treating liver fibrosis, inflammation or associated diseases using an angptl4 antagonist
PE20251067A1 (es) * 2022-08-02 2025-04-09 Nona Biosciences Suzhou Co Ltd Conjugado anticuerpo-farmaco msln
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
AU2006204001B2 (en) 2005-01-07 2011-06-16 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4 )
PL1962895T3 (pl) 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
TWI488643B (zh) 2015-06-21
PL2516466T3 (pl) 2017-09-29
SMT201700280T1 (it) 2017-07-18
JP6000855B2 (ja) 2016-10-05
NZ600768A (en) 2014-09-26
JP2015145424A (ja) 2015-08-13
JP2013515486A (ja) 2013-05-09
WO2011079257A2 (en) 2011-06-30
HUE034722T2 (en) 2018-02-28
DK2516466T3 (en) 2017-05-15
AU2010336369A1 (en) 2012-07-12
LT2516466T (lt) 2017-05-25
RU2012131547A (ru) 2014-01-27
CA2785158A1 (en) 2011-06-30
PT2516466T (pt) 2017-06-06
ES2628135T3 (es) 2017-08-01
MX337082B (es) 2016-02-11
AR079708A1 (es) 2012-02-15
US20110159015A1 (en) 2011-06-30
US8354103B2 (en) 2013-01-15
TW201132354A (en) 2011-10-01
SI2516466T1 (sl) 2017-06-30
ZA201204507B (en) 2013-02-27
CY1118898T1 (el) 2018-01-10
EP2516466A2 (en) 2012-10-31
AU2010336369B2 (en) 2015-06-04
CA2785158C (en) 2018-07-24
EP2516466B1 (en) 2017-03-15
IL220402A (en) 2016-10-31
BR112012017765A2 (pt) 2017-06-20
US9120851B2 (en) 2015-09-01
SG181784A1 (en) 2012-07-30
AU2010336369C1 (en) 2015-08-27
US20130266574A1 (en) 2013-10-10
MX2012007460A (es) 2012-08-23
RS56009B1 (sr) 2017-09-29
HRP20170524T1 (hr) 2017-06-02
KR20120104613A (ko) 2012-09-21
RU2580045C2 (ru) 2016-04-10
JO3274B1 (ar) 2018-09-16
WO2011079257A3 (en) 2011-08-18
KR101842570B1 (ko) 2018-03-28
CN102741284A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
UY33144A (es) Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana
ECSP13013085A (es) Anticuerpos anti-angptl3 y usos de los mismos
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
PA8849001A1 (es) Anticuerpos de c-met
ECSP10010322A (es) Anticuerpos contra el virus de la influenza y métodos de uso de los mismos
GT201200318A (es) Anticuerpos hacia gdf8 humano
CY1114126T1 (el) Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
MX338754B (es) Anticuerpos humanos contra el factor tisular.
BR112014016299A8 (pt) imunoglobulinas de domínio variável e usos das mesmas
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AR086241A1 (es) Proteinas repetitivas de union a il4/il13 y usos
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
GT201200252A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BR112018000909A2 (pt) imunoconjugados de il22
UY36663A (es) Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
BRPI1013649A2 (pt) anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmo
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3